Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PRAX

Praxis Precision Medicines Inc

Feb 06 • 04:00PM ET

319.57

+13.95 4.56 %

Healthcare • Biotechnology • USA • NASD

Peers: SAGE ITCI ACAD NBIX BHVN AXSM VNDA RLMD HELP DFTX

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO IWC VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-12.90	Insider Own	7.76%	Shs Outstand	27.41M	Perf Week	1.77%
Market Cap	8.76B	Forward P/E	-	EPS next Y	-12.63	Insider Trans	-1.79%	Shs Float	25.28M	Perf Month	9.21%
Enterprise Value	8.49B	PEG	-	EPS next Q	-3.10	Inst Own	83.71%	Short Float	14.83%	Perf Quarter	94.10%
Income	-273.04M	P/S	1174.06	EPS this Y	-28.09%	Inst Trans	-6.47%	Short Ratio	4.89	Perf Half Y	576.05%
Sales	7.46M	P/B	19.69	EPS next Y	3.43%	ROA	-67.20%	Short Interest	3.75M	Perf YTD	8.42%
Book/sh	16.23	P/C	32.78	EPS next 5Y	16.28%	ROE	-75.20%	52W High	326.91 -2.25%	Perf Year	262.20%
Cash/sh	9.75	P/FCF	-	EPS past 3/5Y	44.28% 8.54%	ROIC	-79.49%	52W Low	26.70 1096.89%	Perf 3Y	335.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.87%	Volatility	5.64% 6.23%	Perf 5Y	-58.21%
Dividend TTM	-	EV/Sales	1138.31	EPS Y/Y TTM	-25.33%	Oper. Margin	-3927.51%	ATR (14)	18.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.18	Sales Y/Y TTM	364.98%	Profit Margin	-3658.53%	RSI (14)	60.40	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	5.18	EPS Q/Q	-22.38%	SMA20	4.67%	Beta	2.90	Target Price	570.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	16.05%	Rel Volume	0.59	Prev Close	305.62
Employees	116	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	SMA200	161.62%	Avg Volume	766.14K	Price	319.57
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.06% -100.00%	Trades		Volume	450,787	Change	4.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Wells Fargo	Equal Weight	$282
Dec-15-25	Reiterated	Oppenheimer	Outperform	$250 → $750
Nov-19-25	Initiated	BTIG Research	Buy	$424
Jun-02-25	Resumed	Oppenheimer	Outperform	$97
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Mar-03-25	Reiterated	H.C. Wainwright	Buy	$120 → $105
Feb-11-25	Initiated	Deutsche Bank	Buy	$111
Aug-05-24	Initiated	Oppenheimer	Outperform	$134
Jun-24-24	Initiated	Needham	Buy	$145
Jun-18-24	Initiated	Guggenheim	Buy	$155
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48
Aug-26-21	Initiated	BofA Securities	Buy	$28
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform	$40
Nov-10-20	Initiated	Piper Sandler	Overweight	$65
Nov-10-20	Initiated	Evercore ISI	Outperform	$55
Nov-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 06:40AM	SEQSTER and Praxis expand collaboration to expedite CNS disorder trials (Clinical Trials Arena)
Feb-02-26 09:47AM	Palantir upgraded, Best Buy downgraded: Wall Street's top analyst calls (The Fly)
Jan-15-26 11:35AM	Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus (Insider Monkey)
Jan-13-26 04:30PM	Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy (GlobeNewswire) +6.28%
08:00AM	Loading…
Jan-12-26 08:00AM	Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress (GlobeNewswire)
Jan-11-26 01:07AM	Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) (Insider Monkey)
Jan-09-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 04:45PM	Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments (GlobeNewswire)
Jan-06-26 11:15PM	Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering (GlobeNewswire) +7.23%
04:03PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Dec-30-25 08:05AM	Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide (TipRanks)
Dec-29-25 07:39PM	Why Praxis Precision Medicines Stock Popped Today (Motley Fool) +13.25%
04:32PM	Stocks Settle Lower as Weakness in Big Tech Weighs (Barchart)
10:02AM	Stocks Slip Due to Weakness in Megacap Technology Stocks (Barchart)
08:00AM	Loading…
08:00AM	Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor (GlobeNewswire)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 08:00AM	Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 (GlobeNewswire)
07:44AM	TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment (Insider Monkey)
Dec-09-25 04:01PM	Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy (GlobeNewswire)
12:20AM	Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins (Insider Monkey)
Dec-08-25 10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks) +9.27%
08:00AM	Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies (GlobeNewswire)
Dec-05-25 04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal) +30.54%
04:15PM	Praxis Surges 31%, Hitting Another 3-Year High, On A Surprise Win In Epilepsy (Investor's Business Daily)
12:34PM	Stock Market Today: S&P 500 and Nasdaq Gain For Fourth Straight Day Ahead of Highly-Anticipated Fed Policy Meeting (TheStreet)
12:34PM	Stock Market Today: Nasdaq, Dow Gain As Consumer Sentiment Rises for First Time in Five Months (TheStreet)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 04:10PM	Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
04:01PM	Loading…
04:01PM	Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor (GlobeNewswire)
Dec-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 04:01PM	Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) +12.40%
Nov-20-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -13.33%
Nov-19-25 09:07AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More (24/7 Wall St.)
Nov-06-25 08:00AM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback (GlobeNewswire) -5.63%
Nov-03-25 11:15AM	Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating (Insider Monkey) -8.44%
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-26-25 03:47AM	Meet the Biotech Stock That Just Jumped 251% Higher (Motley Fool)
Oct-22-25 07:41AM	Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor (Insider Monkey)
Oct-17-25 10:09AM	Praxis Precision (PRAX) Triples on Stellar Drug Trial Results (Insider Monkey) +16.77%
09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:49AM	Tesla, Nvidia, Rigetti, Praxis: Trending Stocks (Yahoo Finance Video)
Oct-16-25 11:45PM	Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering (GlobeNewswire) +183.71%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
03:49PM	Praxis Precision surges, analysts see blockbuster potential for ulixacaltamide (Investing.com)
02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
12:07PM	A Treatment for Tremors Is Back From the Dead. This Stock Is Up 200%. (Barrons.com)
11:53AM	The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% (Investor's Business Daily)
11:35AM	This Strong Buy Stock Has More Than Tripled Today. Should You Buy It Here? (Barchart)
08:21AM	A longshot bet on a tremor drug pays off (BioPharma Dive)
07:00AM	Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor (GlobeNewswire)
Oct-02-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update (Business Wire)
Sep-04-25 04:01PM	Praxis Precision Medicines to Participate in September Investor Conferences (GlobeNewswire)
Sep-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire)
Aug-25-25 04:01PM	Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline (GlobeNewswire)
Aug-06-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 06:09PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -6.46%
07:38AM	Praxis vormatrigine eliminates seizures in 22% of patients in Phase II trial (Clinical Trials Arena)
03:01AM	Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... (GuruFocus.com)
Aug-04-25 08:24PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -5.55%
01:38PM	Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures (Benzinga)
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
08:23AM	A brain biotech slumps even with best case seizure data (BioPharma Dive)
08:00AM	Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine (GlobeNewswire)
Jul-29-25 08:00AM	Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-17-25 08:00AM	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.30%
Jun-24-25 05:42PM	Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) (Insider Monkey) +5.60%
Jun-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Conferences (GlobeNewswire) +6.29%
May-05-25 08:00AM	Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event (GlobeNewswire)
May-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 08:00AM	Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies (GlobeNewswire) -9.29%
Apr-03-25 05:00PM	Praxis Precision Medicines to Participate in Upcoming April Conferences (GlobeNewswire) -10.27%
04:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-24-25 08:00AM	Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.93%
08:05AM	Praxis Precision price target lowered to $85 from $150 at Needham (TipRanks)
08:00AM	Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 09:10AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -40.64%
08:00AM	Praxis Precision Medicines Provides Update on Essential3 and Corporate Update (GlobeNewswire)
06:40AM	Praxis hits trial setback; Bristol Myers lays off staff in New Jersey (BioPharma Dive)
Feb-25-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.68%
Feb-03-25 05:00PM	Praxis Precision Medicines to Present at Two February Investor Conferences (GlobeNewswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-06-25 08:00AM	Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:00AM	Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome (GlobeNewswire)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire) -8.18%
Dec-03-24 08:00AM	Praxis Precision Medicines to Present at Upcoming December Investor Conferences (GlobeNewswire) -7.39%
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire) +6.67%
Nov-07-24 02:08AM	Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... (GuruFocus.com)

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Option Exercise	73.76	25,130	1,853,531	45,962	Nov 21 09:41 PM
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Sale	193.09	25,130	4,852,256	20,832	Nov 21 09:41 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Option Exercise	61.12	13,600	831,257	24,042	Nov 21 09:39 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Sale	192.08	13,600	2,612,244	10,442	Nov 21 09:39 PM
Nemiroff Alex	Officer	Nov 20 '25	Proposed Sale	193.09	25,130	4,852,249		Nov 20 11:34 AM
Mastrocola Lauren	Officer	Nov 20 '25	Proposed Sale	192.08	13,600	2,612,239		Nov 20 11:25 AM
MITCHELL DEAN J	Director	Sep 24 '25	Option Exercise	39.51	12,251	483,991	17,251	Sep 25 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRAX

Praxis Precision Medicines Inc

Upgrade your FINVIZ experience